Ranibizumab or aflibercept for diabetic macular edema. comparison of 1-year outcomes from the fight retinal blindness registry
International Journal of Development Research
Ranibizumab or aflibercept for diabetic macular edema. comparison of 1-year outcomes from the fight retinal blindness registry
Received 14th June 2020; Received in revised form 28th July 2020; Accepted 07th August 2020; Published online 30th September 2020
Copyright © 2020, Călugăru and Mihai Călugăru. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The authors are commenting on the study entitled “Ranibizumab or aflibercept for diabetic macular edema. Comparison of 1-year outcomes from the fight retinal blindness registry”, published by Bhandari et al. in Ophthalmology 2020;127(5):608-615, which compared the 12-month treatment outcomes of ranibizumab and aflibercept in 383 treatment-naïve eyes with diabetic macular edema. The authors found that aflibercept had somewhat better anatomic outcomes and larger visual acuity gains only in eyes receiving aflibercept treatment when the initial visual acuity was 68 letters or fewer. We believe that these findings can only be validated by statistical analyses including all the missing baseline potential predictive factors referred to above by us in addition to the baseline characteristics already evaluated in this study, serving to emphasize the key metrics assessing the comparative efficacy of ranibizumab and aflibercept in diabetic macular edema.
